{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:44:48Z","timestamp":1792500288889,"version":"4.5.0"},"reference-count":31,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR132948"],"award-info":[{"award-number":["NIHR132948"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\"><jats:title>Background<\/jats:title>\n<jats:p>Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and are routinely used to treat various other eye conditions. However, anti-vascular endothelial growth factor drugs are expensive relative to current care options, and it is unclear whether this additional cost is justified when the immediate risk of vision loss is lower compared to patients with more aggressive ophthalmological conditions.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-2\"><jats:title>Objective<\/jats:title>\n<jats:p>To systematically review the evidence supporting the cost-effectiveness of alternative treatments for diabetic retinopathy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-3\"><jats:title>Methods<\/jats:title>\n<jats:p>A systematic review of all comparative cost-effectiveness studies evaluating any treatment for diabetic retinopathy was conducted. Bibliographic searches were carried out to identify studies reporting on the cost-effectiveness of treatments for diabetic retinopathy; the latest searches were conducted on 28 April 2023. Included studies were synthesised narratively and evaluated with reference to UK decision-making. Studies were grouped by population into non-proliferative diabetic retinopathy and proliferative diabetic retinopathy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-4\"><jats:title>Results<\/jats:title>\n<jats:p>The review identified five studies in the proliferative diabetic retinopathy population, all of which examined the cost-effectiveness of anti-vascular endothelial growth factor treatments compared to pan-retinal photocoagulation. Results of these studies suggest that anti-vascular endothelial growth factor treatments offer some additional benefits in terms of preserved visual acuity but also incur substantial additional costs relative to pan-retinal photocoagulation. Most authors agreed that the additional costs outweigh the limited benefits, especially in certain patient subgroups without pre-existing oedema. As most of the identified evidence considered a US perspective, it is unclear how these results would translate to a UK setting.<\/jats:p>\n<jats:p>Two studies were identified in the non-proliferative diabetic retinopathy population. There was limited evidence to support the early use of anti-vascular endothelial growth factor treatment. However, one UK study suggested that early treatment of non-proliferative diabetic retinopathy with pan-retinal photocoagulation is cost-effective compared to delayed pan-retinal photocoagulation.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-5\"><jats:title>Conclusions<\/jats:title>\n<jats:p>Overall, there is a dearth of cost-effectiveness evidence considering the UK context. The identified studies raised doubts about the cost-effectiveness of anti-vascular endothelial growth factor treatments for proliferative diabetic retinopathy. No conclusions can be made regarding the cost-effectiveness of anti-vascular endothelial growth factor treatments for non-proliferative diabetic retinopathy. Future research should focus on developing rigorous model-based cost-effectiveness analyses integrating all available evidence.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"abs1-6\"><jats:title>Funding<\/jats:title>\n<jats:p>This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR132948.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/nhyk3694","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T08:20:01Z","timestamp":1738225201000},"page":"1-19","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":true,"given":"Robert","family":"Hodgson","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3689","authenticated-orcid":true,"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-1099","authenticated-orcid":true,"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-9109","authenticated-orcid":true,"given":"Laura","family":"Bojke","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7363","authenticated-orcid":true,"given":"Ruth","family":"Walker","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5136","authenticated-orcid":true,"given":"Alexis","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-0221","authenticated-orcid":true,"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-4724","authenticated-orcid":true,"given":"Lesley","family":"Stewart","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-3089","authenticated-orcid":true,"given":"David","family":"Steel","sequence":"additional","affiliation":[{"name":"International Centre for Life, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lawrenson","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Sciences City, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-0381","authenticated-orcid":true,"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-8515","authenticated-orcid":true,"given":"Mark","family":"Simmonds","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"key2025061712571500_ref1-bib1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","article-title":"Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs","volume":"29","author":"Hex","year":"2012","journal-title":"Diabet Med"},{"key":"key2025061712571500_ref2-bib2","volume-title":"Diabetic Retinopathy Guidelines","author":"The Royal College of Ophthalmologists","year":"2013"},{"key":"key2025061712571500_ref3-bib3","volume-title":"Ranibizumab for Treating Diabetic Macular Oedema","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2025061712571500_ref4-bib4","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2025061712571500_ref5-bib5","volume-title":"Aflibercept for Treating Diabetic Macular Oedema","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2025061712571500_ref6-bib6","article-title":"Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis","author":"Simmonds","year":"2023","journal-title":"NIHR J Lib"},{"key":"key2025061712571500_ref7-bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"key2025061712571500_ref8-bib8","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"key2025061712571500_ref9-bib9","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"key2025061712571500_ref10-bib10","doi-asserted-by":"crossref","first-page":"v","DOI":"10.3310\/hta19510","article-title":"Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation","volume":"19","author":"Royle","year":"2015","journal-title":"Health Technol Assessment"},{"key":"key2025061712571500_ref11-bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/eme05050","article-title":"Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT","volume":"5","author":"Sivaprasad","year":"2018","journal-title":"Efficacy Mech Eval"},{"key":"key2025061712571500_ref12-bib12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamaophthalmol.2017.0837","article-title":"Cost-effectiveness of intravitreous ranibizumab compared with panretinal photocoagulation for proliferative diabetic retinopathy: secondary analysis from a diabetic retinopathy clinical research network randomized clinical trial","volume":"135","author":"Hutton","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"key2025061712571500_ref13-bib13","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/jamaophthalmol.2019.4284","article-title":"Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial","volume":"137","author":"Hutton","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"key2025061712571500_ref14-bib14","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.ophtha.2016.05.037","article-title":"Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"123","author":"Lin","year":"2016","journal-title":"Ophthalmology"},{"key":"key2025061712571500_ref15-bib15","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ophtha.2018.02.038","article-title":"Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"125","author":"Lin","year":"2018","journal-title":"Ophthalmology"},{"key":"key2025061712571500_ref16-bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.oret.2021.09.005","article-title":"A cost-effectiveness analysis of intravitreal aflibercept for the prevention of progressive diabetic retinopathy","volume":"6","author":"Patel","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"key2025061712571500_ref17-bib17","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"key2025061712571500_ref18-bib18","first-page":"2137","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2016","journal-title":"JAMA"},{"key":"key2025061712571500_ref19-bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0039-6257(02)00457-5","article-title":"Health care economic analyses and value-based medicine","volume":"48","author":"Brown","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"key2025061712571500_ref20-bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/ICU.0b013e3283523fc1","article-title":"Preference-based comparative effectiveness and cost\u2013effectiveness: a review and relevance of value-based medicine for vitreoretinal interventions","volume":"23","author":"Brown","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"key":"key2025061712571500_ref21-bib21","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (clarity): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"key2025061712571500_ref22-bib22","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the panorama randomized clinical trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"key2025061712571500_ref23-bib23","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0161-6420(98)91020-X","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes","volume":"105","author":"Klein","year":"1998","journal-title":"Ophthalmology"},{"key":"key2025061712571500_ref24-bib24","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes","volume":"115","author":"Klein","year":"2008","journal-title":"Ophthalmology"},{"key":"key2025061712571500_ref25-bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0002-9394(99)00146-4","article-title":"Utility values and diabetic retinopathy","volume":"128","author":"Brown","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"key2025061712571500_ref26-bib26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0002-9394(01)01364-2","article-title":"Vision loss among diabetics in a group model Health Maintenance Organization (HMO)","volume":"133","author":"Fong","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"key2025061712571500_ref27-bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s11136-008-9399-1","article-title":"Lower visual acuity predicts worse utility values among patients with type 2 diabetes","volume":"17","author":"Smith","year":"2008","journal-title":"Qual Life Res"},{"key":"key2025061712571500_ref28-bib28","author":"The Royal College of Ophthalmologists","year":"2012"},{"key":"key2025061712571500_ref29-bib29","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"key2025061712571500_ref30-bib30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"key2025061712571500_ref31-bib31","article-title":"Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and IPD meta-analysis","author":"Simmonds","year":"2024","journal-title":"NIHR J Lib"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/NHYK3694\/NHYK3694.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:32:47Z","timestamp":1750145567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/NHYK3694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":31,"alternative-id":["10.3310\/NHYK3694"],"URL":"https:\/\/doi.org\/10.3310\/nhyk3694","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"08-2021","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"10-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"08-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}